Proteome Systems has announced the appointment of two new non-executive directors prior to the Company's proposed initial public offering
Proteome Systems has announced the appointment of two new non-executive directors prior to the Company's proposed initial public offering.
The appointment of Graham Bradley as non-executive chairman, and Phillip Morley as non-executive director will further strengthen the leadership of the Company, particularly in the areas of business and financial management and governance of ASX listed companies.
They will join current executive directors, Dr Keith Williams and John Martin and non-executive director Neill Colledge who is a senior portfolio manager and head of research for Australian equities in Queensland Investment Corporation.
"The new directors' experience and skills in senior executive management roles in fast growing Australian publicly listed companies will be of great value as Proteome Systems prepares for the announcement of its initial public offering," said Keith Williams, Ph.D., CEO of Proteome Systems.
The Company has appointed Patersons Securities as the lead manager and underwriter for the IPO and will announce the IPO timetable shortly.
The Patersons team is led by Ray Shorrocks who is experienced in managing IPOs for biotechnology companies in Australia.
Graham Bradley previously served as chief executive officer of one of Australia's major listed funds management and financial services groups, Perpetual Trustees Australia Limited.
He also served as managing partner and chief executive officer of a national law firm, Blake Dawson Waldron and was a senior partner of McKinsey and Company. He is a director of MBF Australia Limited, the Garvan Institute of Medical Research, Stockland Corporation Limited, Singapore Telecommunications Limited and chairman of the Film Finance Corporation of Australia Limited.
Phillip Morley is a senior financial executive with over 25 years experience in multi-national companies at corporate, divisional and operational levels.
He is the retiring chief financial officer of James Hardie Industries, where he has served for more than 20 years. Previously, Phillip had financial roles with Burns Philip Limited and Pfizer Phillip is a Director of Bradken Limited.
